RESULTS

Blood PK samples were collected pre-dose and at 1, 2, 4, 6, 8, 10, 12, and 24 hours post-dose. One treatment cycle is 28 days (4 weeks).

PI3K mutation

AKT1, 2, 3 genetic alterations, activating PI3K mutations, PTEN-null, or other known actionable PTEN mutations

Day 22 ARQ 751 Mean Plasma Concentration-Time Profiles

Preliminary Pharmacokinetics (PK)

Day 22 ARQ 751 Mean Plasma PK Parameters

Mean glucose and insulin levels generally correlate with ARQ 751 plasma concentration. As the ARQ 751 drug plasma concentration and indicate ARQ 751 is achieving greater than dose proportional plasma exposure.

CONCLUSIONS

Preliminary anti-tumor activities were observed.

Dose escalation is ongoing.